Abbott forms US pact to develop rapid acute renal failure urine test
This article was originally published in Clinica
Executive Summary
Abbott has signed an exclusive agreement with Cincinnati Children's Hospital (CCH) to develop a urine test for acute renal failure (ARF) based on a marker that has recently emerged as a tool that could "transform the clinical approach to kidney disease". The biomarker, known as NGAL (neutrophil gelatinase-associated lipocalcin), was last year also exclusively licensed to Biosite to make serum and plasma-based tests (see Clinica No 1167, p 18).